Change in fair value of common stock warrant liabilities
3,940
-3,300
-21,275
15,380
Issuance costs allocated to common stock warrant liabilities
-
-
0
0
Collaboration and license agreement receivable
6,000
-5,000
-12,500
17,500
Prepaid and other assets
-624
1,205
-495
500
Accounts payable
1,261
-1,680
428
-1,798
Accrued expenses and other liabilities
-1,451
-1,536
928
3,312
Deferred revenue
-12,692
-12,648
-8,687
-1,565
Net cash (used in) provided by operating activities
-18,762
-22,343
-1,998
-17,495
Purchases of property and equipment
19
556
95
0
Net cash used in investing activities
-19
-556
-95
0
Proceeds from issuance of prefunded warrants and common stock warrants in connection with a follow-on offering, net of issuance costs
-
-
47,033
-
Proceeds from the issuance of common stock, prefunded warrants and liabilities to issue common stock in connection with the exercise of series b warrants, net of issuance costs
-
-
35,828
-
Proceeds from issuance of common stock in connection with sale of stock-Follow On Offering
-
-
-
-285
Proceeds from issuance of common stock-Exercise Of Prefunded Warrants
-
-
1
-
Proceeds from issuance of common stock-Private Placement Abbvie Inc.Stock Purchase Agreement
-
-
0
0
Proceeds from issuance of prefunded warrants in connection with a follow-on offering, net of issuance costs
0
37,256
-
-
Proceeds from issuance of common stock
4,458
0
0
0
Proceeds from issuance of common stock under employee stock purchase plan
36
-
36
0
Proceeds from exercise of stock options
0
1
1
0
Payments of issuance costs included in accounts payable or accrued expenses at prior year end
0
1,550
-
-
Net cash provided by financing activities
4,494
35,707
35,866
-285
(decrease) increase in cash, cash equivalents and restricted cash
-14,287
12,808
33,773
-17,780
Cash, cash equivalents and restricted cash, beginning of period
152,146
139,338
105,565
57,073
Cash, cash equivalents and restricted cash, end of period
137,859
-
-
-
Capital expenditures included in accounts payable or accrued expenses
10
-
-
-
Settlement of liabilities to issue common stock by issuing common stock
7,332
-
-
-
Restricted cash
1,819
-
-
-
Cash, cash equivalents and restricted cash, end of period
137,859
152,146
139,338
105,565
Cash and cash equivalents
136,000
-
-
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.